Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P60174

UPID:
TPIS_HUMAN

ALTERNATIVE NAMES:
Methylglyoxal synthase; Triose-phosphate isomerase

ALTERNATIVE UPACC:
P60174; B7Z5D8; D3DUS9; P00938; Q6FHP9; Q6IS07; Q8WWD0; Q96AG5

BACKGROUND:
Triosephosphate isomerase, with alternative names Methylglyoxal synthase and Triose-phosphate isomerase, is a key enzyme in energy metabolism, facilitating the conversion between key glycolytic intermediates. Additionally, it inadvertently produces methylglyoxal, impacting cellular components.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Triosephosphate isomerase could open doors to potential therapeutic strategies. Its direct link to Triosephosphate isomerase deficiency, a disease with severe metabolic and muscular implications, positions it as a prime candidate for drug target exploration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.